Sponsor content

Astex targets CNS with fragment-based approach

Building on success in the oncology field, Astex Pharmaceuticals is applying its fragment based drug discovery (FBDD) platform to new neurodegenerative disease targets.

Go to the profile of Astex Pharmaceuticals
Oct 25, 2016
1
0
Upvote 1 Comment
Page of
Go to the profile of Astex Pharmaceuticals

Astex Pharmaceuticals

Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system.
0 Contributions
7 Followers
0 Following

Please sign in or register for FREE to comment